Aim of the performed clinical study was to compare the accuracy and cost-effectiveness of PET/CT in the staging of @entity1149 ( @entity1149 ). Material and Methods. Cross-sectional and prospective study including 103 @entity1 with histologically confirmed @entity1149 . All @entity1 were examined using PET/CT with intravenous contrast medium. Those with disease stage  <=IIB underwent surgery (n = 40). Disease stage was confirmed based on histology results, which were compared with those of PET/CT and positron emission tomography (PET) and computed tomography (CT) separately. 63 @entity1 classified with >= IIIA disease stage by PET/CT did not undergo surgery. The cost-effectiveness of PET/CT for disease classification was examined using a decision tree analysis. Results. Compared with histology, the accuracy of PET/CT for disease staging has a positive predictive value of 80%, a negative predictive value of 95%, a sensitivity of 94%, and a specificity of 82%. For PET alone, these values are 53%, 66%, 60%, and 50%, whereas for CT alone they are 68%, 86%, 76%, and 72%, respectively. Incremental cost-effectiveness of PET/CT over CT alone was    17,412 quality-adjusted life-year (QALY). Conclusion. In our clinical study, PET/CT using intravenous contrast medium was an accurate and cost-effective method for staging of @entity1 with @entity1149 .

(18)F-fluorodeoxyglucose positron emission tomography/computed tomography accuracy in the staging of XXXX : review and cost-effectiveness.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['non-small cell lung cancer', 'NSCLC']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']
